New research has pinpointed gene signatures that determine what immune responses will be activated in the development of sepsis, pointing to novel targets and opening the way for the stratification of clinical trials and for patients to be treated on the basis of their immune response, rather than their symptoms.
Odyssey Therapeutics Inc. has described receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of autoimmune diseases, chronic granulomatous disease, neurodegeneration, inflammatory disorders and cancer.
Systemic sclerosis is an autoimmune disorder characterized by inflammation, vasculopathy and fibrosis, mainly affecting internal organs and the skin. There is still a lack of therapies for SSc-induced skin fibrosis.
Optimism on Wall Street proved wise and shares of Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) rose accordingly to close June 17 at $33, up $7.08, or 27.3%, as the firm disclosed interim results from two phase IIb studies evaluating volixibat, an oral ileal bile acid transporter (IBAT) inhibitor, in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The drug proved its mettle in both liver biliary tract-stenosing indications, with no new safety signals turning up, Foster City, Calif.-based Mirum said.
Enveda Biosciences (Enveda Therapeutics Inc.) has announced a new series B2 financing round of $55 million. The drug discovery and development company uses artificial intelligence (AI)-powered technologies to translate nature into new medicines.
The immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein VAV1 plays a key role in mediating T-cell receptor (TCR) and B-cell receptor (BCR) activity and signaling.
Santa Ana Bio Inc. has emerged from stealth with $168 million in combined series A and B funding and a focus on developing targeted therapies for patients with autoimmune and inflammatory diseases.
At the ongoing EULAR meeting, Nektar Therapeutics Inc. presented the first preclinical data on its anti-TNFR2 agonist antibody – NKTR-0165 – for the potential treatment of autoimmune and chronic inflammatory diseases.
Santa Ana Bio Inc. launched with combined series A and B rounds that pulled down $168 million for its precision immunology push in inflammatory diseases, with an aim of entering the clinic next year across several fronts.
Acepodia Inc.’s antibody cell conjugation platform could change the way CAR T-cell therapies are manufactured, clearing the way for an off-the-shelf model to treat numerous cancers that is safer and cheaper than current CAR Ts, Acepodia CEO Sonny Hsiao told BioWorld.
RSS
